Development and Preliminary Validation of a Rapid Progestin-Based Endocrine Disruption Screening Assay

Award Information
Agency: Environmental Protection Agency
Branch: N/A
Contract: 68D02023
Agency Tracking Number: 68D02023
Amount: $70,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2002
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
1414 S. Sangre Road, Stillwater, OK, 74074
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Douglas Fort
 () -
Business Contact
Phone: (405) 624-6771
Research Institution
Concerns regarding the presence of endocrine disruptors in food, water, or other environmental media as well as concerns about the potential risk they pose to humans and wildlife have been growing in recent years. Passage in 1996 of the Food Quality Protection Act and Amendments to the Safe Drinking Water Act reflected these concerns and required the U.S. Environmental Protection Agency to develop a screening program, using appropriate validated test systems and other scientifically relevant information, to determine whether certain substances may have an endocrine effect in wildlife and humans. The proposed work will result in the validation of an assay that tests substances that might disturb reproductive and developmental processes in animals by interfering with the endocrine system. The primary goal of the proposed research is to validate and commercialize the Xenopus laevis oocyte maturation germinal vesicle breakdown (GVBD) model as a system for the rapid evaluation of endocrine-disrupting chemicals (EDCs) found in the workplace or the environment. Specifically, Fort Environmental Laboratories, Inc., will validate and standardize a 24-hour X. laevis assay designed to evaluate progestin-active or antiprogestin EDCs in vitro by conducting an interlaboratory validation study with a series of known mammalian EDCs, compounds found to be inactive, and chemicals with unknown activity. Because none of the currently developed EDC screening systems are capable of specifically screening for progesterone-active EDCs, the successful completion of the in vitro oocyte GVBD model development will provide the scientific community with a nonmammalian, cost-effective, rapid, and reliable method of prescreening EDCs. The ability to rapidly and cost effectively screen for and evaluate the mechanisms of EDCs is an attractive alternative to the current laborious and expensive testing systems used today. Increasing concern over the widespread finding of EDCs in the environment has dramatically increased the need for standardized assays, such as the X. laevis GVBD model, because few other progestin/antiprogestin-based in vitro assays are available today.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government